Financials data is unavailable for this security.
View more
Year on year China Resources Pharmaceutical Group Ltd grew revenues 12.16% from 218.18bn to 244.70bn while net income improved 10.11% from 3.50bn to 3.85bn.
Gross margin | 15.78% |
---|---|
Net profit margin | 3.31% |
Operating margin | 4.65% |
Return on assets | 3.19% |
---|---|
Return on equity | 7.95% |
Return on investment | 12.13% |
More ▼
Cash flow in CNYView more
In 2023, China Resources Pharmaceutical Group Ltd increased its cash reserves by 61.92%, or 9.43bn. The company earned 15.55bn from its operations for a Cash Flow Margin of 6.35%. In addition the company used 2.07bn on investing activities and also paid 4.07bn in financing cash flows.
Cash flow per share | 2.00 |
---|---|
Price/Cash flow per share | 2.84 |
Book value per share | 8.38 |
---|---|
Tangible book value per share | 3.30 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.37 |
---|---|
Quick ratio | 1.12 |
Total debt/total equity | 1.57 |
---|---|
Total debt/total capital | 0.4396 |
More ▼
Growth rates in CNY
SmartText is unavailable
Div yield(5 year avg) | 2.72% |
---|---|
Div growth rate (5 year) | 7.05% |
Payout ratio (TTM) | 39.44% |
EPS growth(5 years) | 2.81 |
---|---|
EPS (TTM) vs TTM 1 year ago | 2.57 |
More ▼